Breakthrough! Clinical trials have shown that ethnosatod is effective in patients with COVID-19 severe disease!

, June 28, 2020 /PRNewswire/
-- New evidence suggests that a 2,000-year-old drug may offer hope for fighting a COVID-19the drug, called autumn daffodil, is a pill-like anti-inflammatory drug used to treat gout, a type of arthritis that dates back centuriesThe drug originally came from autumn saffrondoctors also sometimes use autumn daffodils to treat cabbage, in which case the sacs around the heart become inflamedNow, a team of Greek researchers recently reported on JAMA Network Open that their small trials suggest that autumn daffodils may actually help contain severe COVID-19photo source: The trial involved 105 Greek patients hospitalized in April this year for COVID-19In addition to receiving standardantibiotics
and antiviral drugs (excluding Redsewe), half of the participants took autumn daffodil searlyanine daily for three weeks, while the other half did notThe team, ledby DrSpyridon Deftereos, a cardiologist at Attikon Hospital in Greece, said the results "show significant clinical benefits for COVID-19 hospitalizations." Specifically, seven out of 50 patients who did not take adaffration had a "clinical deterioration" to a critical stage (e.g., mechanical ventilation was needed to survive), while only one in 55 patients treated with aphration of achododipha had a condition, the researchers saida group of American doctors said in an editorial in the journal that they agreed with the limitations of the study, but praised the Greek team for "showing us that an old drug may still be new." DrAmir Rabbani, a cardiologist at the University of, and his colleagues stressed in an editorial that the study was too small to provide a clear statement on whether COVID-19 should be treated routinely with a daffodil they say that, as observed in the new study, the effects of autumn daffodils on certain blood markers of heart function suggest that the anti-inflammatory and anticoagulant effects of autumn daffodils may help limit the cardiovascular damage caused by COVID-19 larger-scale experiment is necessary -- and it's under way
Rajiv Bahl, an emergency physician in Orlando, Florida, has seen first-hand the damage caused by severe COVID-19 After reading the Greek findings, he noted that autumn daffodils "are also used to prevent periactive and other inflammation that affects the body." however, Bahl said the new study is still too small, so while it "does show some hope at an early stage, further research is needed before we can use autumn daffodils as a widely used drug to help fight COVID-19." As first reported in April, researchers in the United States and Canada are testing the ability of ethnoline to prevent high-risk COVID-19 patients from getting serious lying in hospital "One of the unique aspects is that we're trying to solve this problem before people need to be hospitalized," said Dr , according to researcher Dr Priscilla Hsue, a professor of medicine at the University of California, San Francisco Hsue explains that autumn daffodil is the preferred drug for several reasons: Unlike many drugs tested in hospitals, they are infusions or injections, and autumn daffodil tablets are easy to take and are not expensive, so they are easy to use at home She added that the safety of the drug in gout also has a long history , Hsue added, a recent trial found that low doses of autumn daffodils are beneficial for people with recent heart attacks Patients taking one tablet a day have a lower risk of further heart complications or stroke
over the next two years researchers suspect, at least in part, that the immune system, known as a cytokine storm, is out of control unique design
Hsue thinks it's worth studying whether autumn daffodils can help prevent such heart problems North American trial scored 6,000 newly diagnosed PATIENTS with COVID-19 who were at higher risk of serious illness because they were over 69 years of age or had diseases such as heart disease or lung disease in order to isolate these patients from their homes, the study adopted an unusual "non-contact" design in which patients receive medication by courier and follow up by video or phone The researchers will examine whether this strategy can reduce hospitalization and mortality within a month Dr , Dr Randy Cron, a professor of pediatrics and medicine at the University of Alabama at Birmingham, is also an expert on cytokine storms picture source: While Cron believes it is wise to target cytokine storms in COVID-19, he has reservations about using ethnogenic acid for people who show no signs of severe immune response Does suppressing their immune response to the virus backfire? "I'm worried, is it going to make the infection worse?" Cron said However, Hsue pointed to the drug's safety record and noted that the dose given in the trial would be lower than the regular dose of gout finally, experts say the only way to clearly prove that any drug is effective for COVID-19 is to through clinical trials 's Autumn Daffodil study is currently recruiting patients, with the University of California, San Francisco and New York University School of Medicine among the first of the two U.S institutions involved (biovalleybioon.com) references: In early trial, an ancient drug show against against st CERVID-19
Spyridon Deftereos et al.
Effect of the Colchiine vs Standard Care on Cardia c and The Sein A Ciqueos in Patients SEAed With Coronavirus Disease 2019 The GRECCO-19 Random Ized Clinical Trial JAMA Netw Open 2020;3 (6): e2013136 doi: 10.1001/jamanetworkopen.2020.13136